The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fantastic news and a very big well done to Futura getting into the u s market with a first class large pharmaceutical company in Haleon.
The sales flow really is getting underway: from a design in a small lab to world wide sales is a first class achievement
None bigger in consumer health than HALEON. Well done all.
Well the traders who sold down in the last couple of weeks were caught napping and will have been scrambling to buy back in this morning. This will catch the attention of institutions now IMO given such a strong partnership with Haleon. Exciting times now as we have the worlds biggest market being primed to expect Eroxon on the shelves of Walgreens and perhaps the other big retailers depending on the distribution agreement.
Excellent news this morning which should put all those naysayers to the sword once and for all.
Haleon, last years spin off of the retail division of GSK, is a highly regarded FTSE 100 Company which has jumped at the opportunity of extending its considerable OTC clout in the USA with what is certainly a milestone agreement as far as FUTURA is concerned and won’t do HALEON any harm either who’s share price is a little down on its initial launch figure.
Easy to be wise after the event but some of us should perhaps have realised that with JOHN CLARKE, FUM’s chair , and the excellent KEN JAMES both being GSK ‘ old boys’ there was a connection between FUTURA and HALEON well worth expanding.
Forget detrimental or adverse comment from supposed dissatisfied purchasers many of who’s
Comments appear to be suspect ,the fact of the matter is that a highly regarded FOOTSIE 100
Company sees what it likes in FUTURA realises the enormous potential and has acted accordingly .
Good for both Companies and Good for BRITAIN when we all need a bit of good cheer.
Well done J.B. and his team and also all long term FUMSTERS who have kept the faith.
Gla,
Arturo
Now that it has a US partner next target is 75p easily.
I had this on my buy watchlist, but regrettably, I will take a pass on this occasion.
I know Haleon well. This is massive.
Yes, I think it was a joint venture between GSK and Pfizer. Ie the biggest players in pharmaceuticals. There was a Demerger last year when they spun the consumer health division off as Haleon.
That's right. This used to be Beecham Consumer Products, a highly successful and well managed outfit.
Brilliant. Sensodyn sold in evey supermarket in the UK as will Eroxon in the USA.
Can see a 10p dividend next year
They were spun out of GSK if I'm right. Barder using his connections wisely there 😉
Yee Haa,
I hope this also means that sales have been going well enough so far, for Haleon to agree to pick up the baton for USA sales.
Wonder how long it will take Haleon to get organised and put Eroxon on the shelf?
WOW!!! their portfolio includes Sensodyne, Advil, Pandol, and Voltarol, and turnover is $11 billion dollars. This is a massive win for Futura
Did I not say last week that those selling in the low 50’s may come to regret it.Yesterday the Sunday Times recommended the share as a buy .Today we have massive news.
You were mugged!
Totally exclusive?
Here is the morning RNS we have been waiting for. Haleon appointed to commercialise Eroxon in the US. 4 million up front to FUM, royalties on all sales and milestone payments up to 45 million.
USA partner announced.
GLA
Thanks for tidying that up Zoomydoo, I understood it though, There could be a rise in the morning 65% chance I’d say .
The last part of the article is a tongue in cheek referral to a “ happy ending” where a massage with a happy ending finishes off with an ejaculation. Much the same as for the punter who takes Eroxon hoping for an erection and an ejaculation. Hence happy ending
Actually his last statement was "Buy".....the previous bit was just the writer covering their xrse at the end of a VERY positive article.
His last statement doesn’t quite fill me with excitement.
There are no guarantees of a happy ending, but it’s a worthy punt.
He would appear to think it’s not a worthwhile long term investment, but rather a short term “punt”. Hopefully anyone reading the article is greedy enough to consider it rather a worthwhile long-term investment.
Just read it in the Times too. Should add a few pence on Monday!
Don’t get better than the Sunday Times ….good one
Also Sales last few days at boots beating viagra almost 2 to 1 and the new Cialis OTC by 6 to 1
Futura has made a new product that works, and it is only just starting to shout about it.
The company’s Eroxon gel is the first erectile dysfunction product approved to go on sale without a prescription. It is already available at Boots and online via the likes of Amazon, and it is the first new ED treatment for two decades. Clinical trials showed Eroxon successfully pumped up 65 per cent of users. Given the scale of the stigma-ridden, $3 billion (£2.3 billion) global market for men suffering a lack of erections — it is forecast to surpass $6 billion by 2032 — Futura looks appealing.
Rival treatments, such as Viagra and Cialis, both need a prescription and take longer to work: the Eroxon gel acts in ten minutes; it’s half an hour with rivals.
Futura has also minimised risk by outsourcing all it can: it does the science, but then, said chief executive James Barder, looks for “commercial partners to do the rest” — the marketing and distribution. “We’ve done so in the UK, Europe, and seven countries in the Middle East. Saudi [Arabia’s] approval is expected in September — that’s the biggest erectile dysfunction market in the Middle East — and we are working on a US partner .”
America has the world’s highest number of ED sufferers by far, and Barder said Futura had “interest from a number of parties”. Signing a commercial deal there would be likely to trigger a share price surge.
“The announcement of that US partner will be crucial as it’s very early days for Eroxon,” said Seb Jantet, an analyst at house broker Liberum. “But there are early signs of success.”
In the UK, where Futura’s product first hit Boots’s shelves exclusively in April, almost £2 million worth of Eroxon was sold in the first eight weeks, the firm told capital market day attendees last month. Its launch partner said it had been one of its most successful over-the-counter launches.
Futura is anticipating sales of £3 million this year — stocking orders from the small markets of the UK and Belgium. “These don’t really show the scale of what the product could do,” Jantet added. But Futura has more than £4 million in cash and a strong balance sheet. There are no guarantees of a happy ending, but it’s a worthy punt. Buy.
https://www.thetimes.co.uk/article/futura-is-looking-for-rapid-growth-8gpml9kzq
I haven't seen any Eroxon adds on TV for a while. Has anyone else?